Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells

Ibrutinib (PCI-32765) is an irreversible dual Btk/Itk inhibitor shown to be effective in treating several B cell malignancies. However, limited studies have been conducted to study the effect of this drug on myeloid cell function. Hence, we studied the effect of ibrutinib treatment on TLR-4 mediated...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncoimmunology
Auteurs principaux: Natarajan, Gayathri, Terrazas, Cesar, Oghumu, Steve, Varikuti, Sanjay, Dubovsky, Jason A, Byrd, John C, Satoskar, Abhay R
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2015
Sujets:
Brief Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4760285/
https://ncbi.nlm.nih.gov/pubmed/26942065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1057385
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires